Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1593899 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $4.74Day +2.60%Mkt cap $379M1Y +29.2%Off 52W high −26.5%Vol (1Y) 49.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,967 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.7% of sh out |
| Days to cover22.8d |
| 13F net flow (QoQ)+2.40% |
| Top-10 13F concentration74.5% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$351.4M |
| Earnings (TTM)-$169.5M |
| ROE−44.3% |
| ROIC−51.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+32.8% |
| 1Y+29.2% |
| 3Y+38.2% |
| 5Y−81.1% |
| 10Y+251.1% |
| Since incept. (ann.)+8.6% |
Total return through 2026-07-30 · series begins 2016-01-04. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)49.1% |
| Ann. volatility (3Y)47.1% |
| Sharpe (1Y)0.70 |
| Sharpe (3Y)0.47 |
| Max drawdown (1Y)−33.3% |
| Max drawdown (3Y)−44.1% |
| Beta (3Y vs SPY)−0.13 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 12.0M | $64M | 15.00% | +23.5% |
| BlackRock, Inc. | 8.4M | $45M | 10.59% | −0.7% |
| BML Capital Management, LLC | 7.1M | $38M | 8.86% | −5.8% |
| TANG CAPITAL MANAGEMENT LLC | 4.8M | $26M | 6.04% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2M | $17M | 4.07% | new |
| Bain Capital Life Sciences Investors, LLC | 2.4M | $13M | 2.96% | −5.0% |
| TWO SIGMA INVESTMENTS, LP | 1.9M | $10M | 2.34% | +150.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $9M | 2.19% | −5.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.57 | — | — | — |
| 2025-09-30 | 2025-11-12 | −$0.53 | — | — | — |
| 2025-06-30 | 2025-08-07 | −$0.44 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.40 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
